Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
China patients in end stage renal disease receiving maintenance dialysis have a high risk of cardiovascular disease (CVD), with a prevalence of 45.5% approximately, and coronary artery disease (CAD) has been identified as the most common one. It remains unclear that what their treatment status is and whether this group of patients can benefit from revascularization in China. The investigators plan to recruit around 30 hospitals from 7 regions as study centers, which represent different levels of economic development in Mainland China. The detailed information includes demographics, medical history, coronary angiogram, in-hospital treatment and procedures, short-term and long-term outcomes. The aim of the study is to provide the real world knowledge about current status of coronary revascularization and prognosis in patients with CAD and dialysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Revascularization group | This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease. |
| |
| Medical treatment group | This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Revascularization | Other | Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of all-cause death | All-cause deaths includes cardiac death, vascular death and non-cardiovascular death.
| the duration of hospital stay, an expected average of 2 weeks |
| Incidence of all-cause death and non-fatal myocardial infarction | Non-fatal myocardial infarction is defined as elevated cardiac enzymes (troponin or myocardial band fraction of creatine kinase) above the upper reference limit with ischemic symptoms or electrocardiography findings indicative of ischemia that is not related to the index procedure. | 12-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of all-cause death and non-fatal myocardial infarction | Definitions of all-cause death and non-fatal myocardial infarction as mentioned above. | within 30 days after discharge |
| Incidence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, repeat revascularization, cardiovascular rehospitalization. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The population of this study will be selected from around 30 different hospitals in 7 different areas in China.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhengqin Zhai | Contact | +86 18612511571 | zhengqin712@outlook.com |
| Name | Affiliation | Role |
|---|---|---|
| Jingang Zheng | China-Japan Friendship Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship Hospital | Recruiting | Beijing | Beijing Municipality | 100000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002404 | Catheterization |
| D044623 | Nutrition Therapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
| Medical therapy | Other | Optimal medical therapy for coronary artery disease |
|
|
| 12-month follow-up |
| Incidence of bleeding | Bleeding Academic Research Consortium (BARC) type 2 to 5 bleeding. | 12-month follow-up |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |